LOG IN
Analysis
Featured Analysis
Articles by Category
Current Editions
Data Graphics
Discovery & Translation
Hot Topics
BioCentury Podcasts
Special Reports & Presentations
White Papers
BCIQ Data
BCIQ
Company Profiles
Product Profiles
Target Profiles
Financial Dashboards
Events
All Events
East-West Healthcare Reception
Bio€quity Europe
Grand Rounds — U.S.
Grand Rounds — Europe
China Healthcare Summit
East-West Biopharma Summit 2026
Bio€quity Europe 2026
The BioCentury Show
Podcast: BioCentury This Week
Webinars
My Workspace
About BioCentury
Management
Analysts & Research Team
Scientific Advisory Board
Contact
Contact Us
Forgot Password
Request a Subscription
Sponsorship & Branding Inquiry
Media Kit
Request BioCentury's BCIQ Brochure
Customer Resource Center
Career Opportunities
Request a Trial
Company Profiles
Target Profiles
Product Profiles
Latest Articles
Commentaries
Deals
Distillery
Emerging Companies
Finance
Politics, Policy & Law
Product Development
Regulation
Targets & Mechanisms
Tools & Techniques
Company Profiles
Target Profiles
Product Profiles
China Healthcare Summit
Bio€quity Europe
Explore BCIQ profiles by entering a company name.
REQUEST A FREE TRIAL
Overview
Articles
Threshold Pharmaceuticals Inc.
Headquarters:
Menlo Park, CA, United States of America
Website:
N/A
Year Founded:
2001
Status:
Merged
BioCentury
|
Sep 4, 2020
Product Development
Rain to advance growing precision oncology pipeline with $63M series B
A crossover-heavy $63 million series B round will provide Rain with enough money to bring what it says is its new lead program — a newly licensed cancer therapy from Daiichi Sankyo —
Read More
BioCentury
|
May 25, 2018
Financial News
Rain raises $18M to advance tarloxotinib in NSCLC
Read More
BioCentury
|
May 21, 2018
Financial News
Rain raises $18M to advance tarloxotinib in NSCLC
Read More
BioCentury
|
Jun 16, 2017
Clinical News
MD Anderson starts Phase I of evofosfamide plus Yervoy in solid tumors
Read More
BioCentury
|
Jun 14, 2017
Strategy
Threshold to academia
How new vice chancellor Selick plans to reap rewards for UCSF innovations
Read More
BioCentury
|
Jun 9, 2017
Company News
Threshold grants OBI ex-Asian rights to TH-3424
Read More
BioCentury
|
Apr 25, 2017
Company News
UCSF taps Selick for BD position
Read More
BioCentury
|
Mar 24, 2017
Company News
Molecular Templates, Threshold deal
Read More
BioCentury
|
Mar 17, 2017
Company News
Molecular Templates finds public path via Threshold
Read More
BioCentury
|
Dec 30, 2016
Company News
Threshold, NIH deal
Read More
Items per page:
10
1 - 10 of 205